Gimeracil inhibits dihydropyrimidine dehydrogenase, resulting in increased fluorouracil levels in the bloodstream and tumor tissues, whereas potassium terbacil reduces gastrointestinal toxicity by preventing fluorouracil phosphorylation in the gastrointestinal tract [38]. The gene discussed is DPYD; the disease is neoplasm.